Psychedelics Investments

Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items from weeks three and four of January 2024. See previous edition Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD’s Perceived Risks, Knowledge Gaps, Surveys & More  Research...

Ontario-based mushrooms producer Red Light Holland Corp. (OTCQB: TRUFF) filed its interim financial results for the third fiscal quarter of 2023 -three and nine months- ended December 31, 2022. Numbers show a revenue increase of 88.9% and 158% for the three and nine-month periods ended Dec. 31,...

Cybin Inc. (NYSE: CYBN) announced key highlights from its successful feasibility study conducted by its partner HI, LLC dba Kernel that tested its wearable technology to measure ketamine's psychedelic effect on the brain. Results from this Cybin-sponsored study are intended...

Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. Jaguar Health and Filament Health Form JV Jaguar Health Inc. (NASDAQ: JAGX) and Filament Health Corp. (OTCQB: FLHLF), together with Will...

Several weeks ago, Cathie Wood's ARK Fund (BATS: ARKG) invested in the biotech psychedelics sector, specifically in major player Atai Life Sciences (NASDAQ: ATAI).   The first purchase took place in February 2022, when ARK bought 83,278 shares of Atai Life Sciences...

In a new assessment report, the market research & consulting firm InsightAce Analytic stated that the global psychedelic therapeutics market was valued at US$ 3.61 billion in 2021 and is expected to reach US$ 8.31 billion by 2028, with a compound annual growth rate (CAGR) of...